Sugi Predict

Sugi Predict / Compounds / SCHEMBL1970462

SCHEMBL1970462

SCHEMBL1970462

O=C(Cl)OC(=O)OCc1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.71
▸ TDP1 Q9NUW8 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ MAPK1 P28482 1/20 0.53
▸ L3MBTL1 Q9Y468 1/20 0.53
▸ SLC6A2 P23975 1/20 0.53
▸ SLC6A3 Q01959 1/20 0.53
▸ LMNA P02545 3/20 0.49
▸ HCAR2 Q8TDS4 1/20 0.49
▸ TSHR P16473 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ GFER P55789 1/20 0.44
▸ HSD17B10 Q99714 1/20 0.44
▸ CA12 O43570 1/20 0.44
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ CA9 Q16790 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL48133 0.88 ALDH1A1 (0.63) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL10459697 0.86 ALDH1A1 (0.61) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL2537574 0.84 ALDH1A1 (0.59) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL28207255 0.84 ALDH1A1 (0.59) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
Benzene SCHEMBL28101078 0.84 ALDH1A1 (1.00) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL960 0.84 ALDH1A1 (1.00) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL37382 0.83 ALDH1A1 (0.68) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL28942580 0.82 ALDH1A1 (0.96) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
SCHEMBL27316763 0.82 ALDH1A1 (0.96) ALDH1A1TDP1KMT2AMAPK1L3MBTL1
Hydrogen Sulfide SCHEMBL27839115 0.82 ALDH1A1 (0.96) ALDH1A1TDP1KMT2AMAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0248279-B1 Semisynthetic erythromycin antibiotics ABBOTT LAB (US) 1994-08-31 — — EP claimed
EP-0248279-A2 Semisynthetic erythromycin antibiotics ABBOTT LABORATORIES (US) 1987-12-09 — — EP claimed
EP-4640742-A1 ELECTRONIC SUBSTRATE MATERIAL, RESIN, AND METHOD FOR MANUFACTURING RESIN Idemitsu Kosan Co.,Ltd. (JP) 2025-10-29 — — EP disclosed
CN-116063325-A Macrocyclic compounds with BTK modulating effect and uses thereof 赛诺哈勃药业（成都）有限公司 2023-05-05 — — CN disclosed
CN-116063324-A Inhibitors of BTK and/or RET having macrocyclic structure 赛诺哈勃药业（成都）有限公司 2023-05-05 — — CN disclosed
US-8168667-B2 Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such GALAPAGOS NV (BE) 2012-05-01 — — US disclosed
EP-2026799-B1 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH GALAPAGOS SAS (FR) 2011-06-22 — — EP disclosed
US-20100210699-A1 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH DART THERAPUTICS, LLC. 2010-08-19 — — US disclosed
US-20100063120-A1 Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such SASU, GALAPAGOS (FR) 2010-03-11 — — US disclosed
EP-2026799-A2 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH Galapagos SAS (FR) 2009-02-25 — — EP disclosed
US-20080103123-A1 New compounds BIOVITRUM (SE) 2008-05-01 — — US disclosed
EP-0413762-B1 PEPTIDE ANALOGS AND THEIR USE AS HAPTENS TO ELICIT CATALYTIC ANTIBODIES IGEN INT INC (US) 2000-07-12 — — EP disclosed
EP-0659188-A4 METHODS FOR THE SYNTHESIS OF PHOSPHONATE ESTERS. AFFYMAX TECH NV (AN) 1995-11-22 — — EP disclosed
EP-0659188-A1 METHODS FOR THE SYNTHESIS OF PHOSPHONATE ESTERS AFFYMAX TECHNOLOGIES N.V. (AN) 1995-06-28 — — EP disclosed
US-5420328-A Esterification with alcohol and hydrolysis AFFYMAX TECHNOLOGIES, N.V. (AN) 1995-05-30 — — US disclosed
US-5359115-A Reacting phosphonic monoester with dialkylazodicarboxylate, triphenylphosphine and secondary alcohol to form diester, hydrolyzing selective ester to form monoester, coupling an aminoacid to yield peptidylphosphonate AFFYMAX TECHNOLOGIES, N.V. (US) 1994-10-25 — — US disclosed
WO-1994006808-A1 METHODS FOR THE SYNTHESIS OF PHOSPHONATE ESTERS AFFYMAX TECHNOLOGIES N.V. (AN) 1994-03-31 — — WO disclosed
EP-0413762-A4 PEPTIDE ANALOGS AND THEIR USE AS HAPTENS TO ELICIT CATALYTIC ANTIBODIES — 1992-01-15 — — EP disclosed
EP-0413762-A1 PEPTIDE ANALOGS AND THEIR USE AS HAPTENS TO ELICIT CATALYTIC ANTIBODIES IGEN, INCORPORATED (US) 1991-02-27 — — EP disclosed
WO-1989010961-A1 PEPTIDE ANALOGS AND THEIR USE AS HAPTENS TO ELICIT CATALYTIC ANTIBODIES IGEN, INC. (US) 1989-11-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210699-A1 IMIDAZOLIDINE DERIVATIVES, USES THEREFOR, PREPARATION THEREOF AND COMPOSITIONS COMPRISING SUCH NR5A1, AR, HSD17B7 ALDH1A1 300/4885TDP1 2744/4885KMT2A 1222/4885
US-20080103123-A1 New compounds GPR119, GPR139, GPR180 ALDH1A1 1431/4885TDP1 4625/4885KMT2A 4721/4885
US-20100063120-A1 Imidazolidine Derivatives, Uses Therefor, Preparation Thereof and Compositions Comprising Such NR5A1, AR, HSD17B7 ALDH1A1 290/4885TDP1 2743/4885KMT2A 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.